Development and optimization of sustained release triptolide microspheres
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0292861 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Hui-Lin Zeng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Family Planning Commission of Hubei Province.
Abstract (Originalsprache)
Rheumatoid arthritis is considered a chronic systemic autoimmune disorder that may cause joint destruction. Triptolide, an active component isolated from Tripterygium wilfordii Hook.f., is considered to have promising potential for clinical use in treating rheumatoid arthritis. However, its clinical application has been limited by the narrow therapeutic window, side effects associated with plasma drug fluctuations, low oral bioavailability, and poor patient compliance with the long and frequent dosing regimen. An extended drug release preparation may address these limitations. The aim of this work was therefore to develop, formulate and optimize sustained release triptolide microspheres with poly (lactide-co-glycolide) (PLGA). Triptolide-loaded microspheres were prepared using PLGA as the matrix polymer, dichloromethane as the oil phase, and polyvinyl alcohol (PVA) as the matrix forming emulsifier. An oil-in-water (O/W) emulsion solvent evaporation technique was utilized to prepare the microspheres. Surface response methodology (RSM) coupled with central composite design (CCD) was used to optimize the formulation and a total of twenty formulations were prepared. PVA concentration (X 1 ), PLGA concentration (X 2 ), and theoretical drug content (X 3 ) were selected as independent variables; and drug content (Y 1 ), encapsulation efficiency (Y 2 ), mean diameter (Y 3 ) and the initial release during the first day (Y 4 ) were taken as the response variables. The optimized formulation showed mean diameter of 42.36 μm, drug content of 7.96%, encapsulation efficiency of 80.16% and an initial release of 14.48%. The prepared microspheres exhibited a sustained release profile of triptolide in vitro over 4 weeks, which was wellfitted with a Korsmeyer-Peppas equation. However, the initial drug release (~14%) of triptolide-loaded microspheres was very high and should be specifically investigated in future studies. The results indicate that long-term sustained release microspheres of triptolide can be considered a strategy to overcome the low bioavailability and poor patient compliance with conventional triptolide tablets. The issue of initial burst release and in vivo evaluations should be specifically investigated in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, Hubei, China.
ORCID-Profile: Ting-Xiong Fu
Förderung
- Health and Family Planning Commission of Hubei Province
Zitieren
APA
Zeng, H. L., Qiu, Q., Fu, T. X., Deng, A. P., & Xie, X. Y. (2023). Development and optimization of sustained release triptolide microspheres. PLOS ONE. https://doi.org/10.1371/journal.pone.0292861
Vancouver
Zeng HL, Qiu Q, Fu TX, Deng AP, Xie XY. Development and optimization of sustained release triptolide microspheres. PLOS ONE. 2023. doi:10.1371/journal.pone.0292861
BibTeX
@article{Zeng2023,
author = {Zeng, Hui-Lin and Qiu, Qian and Fu, Ting-Xiong and Deng, Ai-Ping and Xie, Xiang-Yang},
title = {Development and optimization of sustained release triptolide microspheres},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0292861}
}
EUVIMED